Your browser doesn't support javascript.
loading
A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern.
van Gils, Marit J; van Willigen, Hugo D G; Wynberg, Elke; Han, Alvin X; van der Straten, Karlijn; Burger, Judith A; Poniman, Meliawati; Oomen, Melissa; Tejjani, Khadija; Bouhuijs, Joey H; Verveen, Anouk; Lebbink, Romy; Dijkstra, Maartje; Appelman, Brent; Lavell, A H Ayesha; Caniels, Tom G; Bontjer, Ilja; van Vught, Lonneke A; Vlaar, Alexander P J; Sikkens, Jonne J; Bomers, Marije K; Russell, Colin A; Kootstra, Neeltje A; Sanders, Rogier W; Prins, Maria; de Bree, Godelieve J; de Jong, Menno D.
Afiliação
  • van Gils MJ; Department of Medical Microbiology & Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • van Willigen HDG; Department of Medical Microbiology & Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Wynberg E; Department of Medical Microbiology & Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Han AX; Department of Infectious Diseases, Public Health Service of Amsterdam, GGD, Amsterdam, the Netherlands.
  • van der Straten K; Department of Medical Microbiology & Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Burger JA; Department of Medical Microbiology & Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Poniman M; Department of Internal Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Oomen M; Department of Medical Microbiology & Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Tejjani K; Department of Medical Microbiology & Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Bouhuijs JH; Department of Medical Microbiology & Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Verveen A; Department of Medical Microbiology & Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Lebbink R; Department of Medical Microbiology & Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Dijkstra M; Department of Medical Psychology, Amsterdam UMC, University of Amsterdam, Amsterdam School of Public Health, Amsterdam, the Netherlands.
  • Appelman B; Department of Infectious Diseases, Public Health Service of Amsterdam, GGD, Amsterdam, the Netherlands.
  • Lavell AHA; Department of Infectious Diseases, Public Health Service of Amsterdam, GGD, Amsterdam, the Netherlands.
  • Caniels TG; Department of Internal Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Bontjer I; Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • van Vught LA; Department of Internal Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Vlaar APJ; Department of Medical Microbiology & Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Sikkens JJ; Department of Medical Microbiology & Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Bomers MK; Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Russell CA; Department of Intensive Care Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Kootstra NA; Department of Intensive Care Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Sanders RW; Department of Internal Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • Prins M; Department of Internal Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • de Bree GJ; Department of Medical Microbiology & Infection Prevention, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
  • de Jong MD; Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
Cell Rep Med ; 3(1): 100486, 2022 01 18.
Article em En | MEDLINE | ID: mdl-35103254
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinação / Anticorpos Neutralizantes / Imunogenicidade da Vacina / SARS-CoV-2 / COVID-19 / Vacina BNT162 / Anticorpos Antivirais Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cell Rep Med Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinação / Anticorpos Neutralizantes / Imunogenicidade da Vacina / SARS-CoV-2 / COVID-19 / Vacina BNT162 / Anticorpos Antivirais Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cell Rep Med Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda País de publicação: Estados Unidos